JOURNAL
Current Issue
Journal Archive
 

Chief Editor -
Abdulrazak Abyad MD, MPH, MBA, AGSF, AFCHSE

.........................................................

Publisher -
Lesley Pocock
medi+WORLD International
AUSTRALIA
Email
: lesleypocock@mediworld.com.au
publishermwi@gmail.com
.........................................................

Editorial Enquiries -
abyad@cyberia.net.lb
.........................................................

Advertising Enquiries -
lesleypocock@mediworld.com.au
.........................................................

While all efforts have been made to ensure the accuracy of the information in this journal, opinions expressed are those of the authors and do not necessarily reflect the views of The Publishers, Editor or the Editorial Board. The publishers, Editor and Editorial Board cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; or the views and opinions expressed. Publication of any advertisements does not constitute any endorsement by the Publishers and Editors of the product advertised.

The contents of this journal are copyright. Apart from any fair dealing for purposes of private study, research, criticism or review, as permitted under the Australian Copyright Act, no part of this program may be reproduced without the permission of the publisher.

WFM / MEJFM August 2023

Low-dose warfarin may be a life-saving treatment regimen in sickle cell diseases

(1) Specialist of Internal Medicine, MD, Turkey
(2) Manager of Writing and Statistics, MD, Turkey
(3) Middle-East Academy for Medicine of Aging, MD, Lebanon
(4) Medi-WORLD International, Australia

Corresponding author:
Prof Dr Mehmet Rami Helvaci, MD
07400, ALANYA, Turkey
Phone: 00-90-506-4708759
Email: mramihelvaci@hotmail.com

Received: June 2023. Accepted: July 2023; Published: August 1, 2023.Citation: Helvaci MR et al. Low-dose warfarin may be a life-saving treatment regimen in sickle cell diseases. World Family Medicine. August 2023; 21(7): 21-35 DOI: 10.5742/MEWFM.2023.95256131

Abstract



Background:
Sickle cell diseases (SCDs) are inborn and destructive processes on vascular endothelium, particularly at the capillaries.

Methods: All patients with the SCDs were included.

Results: We studied 222 males and 212 females with similar ages (30.8 vs 30.3 years, p>0.05, respectively). Disseminated teeth losses (5.4% vs 1.4%, p<0.001), ileus (7.2% vs 1.4%, p<0.001), cirrhosis (8.1% vs 1.8%, p<0.001), leg ulcers (19.8% vs 7.0%, p<0.001), clubbing (14.8% vs 6.6%, p<0.001), coronary heart disease (18.0% vs 13.2%, p<0.05), chronic renal disease (9.9% vs 6.1%, p<0.05), chronic obstructive pulmonary disease (25.2% vs 7.0%, p<0.001), and stroke (12.1% vs 7.5%, p<0.05) were higher in males but not acute chest syndrome (2.7% vs 3.7%), pulmonary hypertension (12.6% vs 11.7), deep venous thrombosis and/or varices and/or telangiectasias (9.0% vs 6.6%), or mean age of mortality (30.2 vs 33.3 years) (p>0.05 for all).

Conclusion: The sickled or just hardened red blood cells (RBCs)-induced capillary endothelial damage initiates at birth, and terminates with multiorgan failures and sudden deaths even at childhood. Although RBCs suspensions and corticosteroids in acute, and aspirin plus hydroxyurea both in acute and chronic phases decrease severity, survivals are still shortened in both genders, dramatically. Infections, medical or surgical emergencies, or emotional stress-induced increased basal metabolic rate accelerates sickling, and an exaggerated capillary endothelial edema-induced myocardial infarction or stroke may cause sudden deaths. Lifelong aspirin with an anti-inflammatory dose plus low-dose warfarin may be life-saving even at childhood both to decrease severity of capillary endothelial inflammation and to prevent thromboembolic complications in the SCDs.

Key words: Sickle cell diseases, sickled or just hardened red blood cells, capillary endothelial edema, myocardial infarction, stroke, sudden deaths, low-dose warfarin






.................................................................................................................

I About MEJFM I Journal I Advertising I Author Info I Editorial Board I Resources I Contact us I Journal Archive I MEPRCN I Noticeboard I News and Updates
Disclaimer - ISSN 148-4196 - © Copyright 2007 medi+WORLD International Pty. Ltd. - All rights reserved